Filtered By:
Drug: Invega
This page shows you your search results in order of date.
Order by Relevance | Date
Total 63 results found since Jan 2013.
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
A Case Report of Stuttering Induced by Risperidone and Chlorpromazine
Psychopharmacol Bull. 2022 Feb 25;52(1):53-56.ABSTRACTStuttering, a disturbance in the normal fluency and time patterning of speech is usually developmental. In some cases, it is acquired, and causes include stroke, brain tumor, and trauma. Implicated in the causation of stuttering are overactive presynaptic dopamine systems in the region of the brain that modulate verbalization. It is a rare side effect of antipsychotic medications and has been reported with phenothiazines, clozapine, and risperidone. This is a report of a patient who developed stuttering when treated first with chlorpromazine and later with risperidone. ...
Source: Psychopharmacology Bulletin - March 28, 2022 Category: Psychiatry & Psychology Authors: Shabnam Sood Source Type: research
